AbbVie Ends Rova-T R&D Program in Small-Cell Lung Cancer -- Update
August 29 2019 - 10:24AM
Dow Jones News
By Colin Kellaher
AbbVie Inc. (ABBV) on Thursday said it is ending its
research-and-development program for Rova-T, the key asset in its
$5.8 billion acquisition of Stemcentrx Inc. in 2016, after the
investigational antibody-drug conjugate showed no survival benefit
in a phase 3 study in advanced small-cell lung cancer.
The North Chicago, Ill., biopharmaceutical company said it will
prioritize other development programs within its oncology
pipeline.
AbbVie said an independent data monitoring committee recommended
terminating the study of Rova-T as a first-line maintenance therapy
for advanced small-cell lung cancer due to lack of survival benefit
for patients receiving Rova-T compared with placebo.
AbbVie in January recorded a $4 billion impairment charge
related to the Stemcentrx deal after it scrapped an earlier phase 3
study evaluating Rova-T as a second-line therapy for advanced
small-cell lung cancer.
The company at the time also said it would monitor the remaining
$1 billion of Stemcentrx intangible assets for further impairment
based on Rova-T clinical development programs.
Small-cell lung cancer is difficult to treat and accounts for
10% to 15% of all lung cancers.
Shares of AbbVie rose less than 1%, to $66.55, in early trading
Thursday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 29, 2019 10:09 ET (14:09 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Mar 2024 to Apr 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Apr 2023 to Apr 2024